Used as a key chiral intermediate in the synthesis of fluorinated pharmaceutical compounds, particularly in the development of protease inhibitors and other biologically active molecules. Its structure allows for selective coupling in peptide synthesis, making it valuable in creating enantiomerically pure drugs. Commonly employed in solid-phase peptide synthesis (SPPS) due to the Fmoc protecting group, enabling mild deprotection conditions. The 2,6-difluorophenyl moiety enhances binding specificity and metabolic stability in final drug candidates, especially in oncology and antiviral therapies.